Collegium Pharmaceutical (COLL) Intangibles (2018 - 2026)

Collegium Pharmaceutical has reported Intangibles for 7 years, with the latest figure at $1.2 billion in Q2 2026.

• On a quarterly basis, Intangibles rose 51.97% year-over-year to $1.2 billion in Q2 2026; TTM through Jun 2026 was $1.2 billion, a 51.97% increase from a year earlier, with the FY2025 full-year figure at $669.5 million, down 24.89% from the prior year.
• Intangibles was $1.2 billion for Q2 2026 at Collegium Pharmaceutical, up from $614.0 million in the prior quarter.
• The five-year high for Intangibles was $1.2 billion in Q2 2026, with the low at $352.7 million in Q2 2024.
• Average Intangibles over 5 years is $783.9 million, with a median of $863.7 million recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Intangibles tumbled 62.92% in 2024, then jumped 121.3% in 2025.
• Over 5 years, Intangibles stood at $567.5 million in 2022, then decreased by 25.69% to $421.7 million in 2023, then soared by 111.38% to $891.4 million in 2024, then declined by 24.89% to $669.5 million in 2025, then surged by 77.16% to $1.2 billion in 2026.
• The last three Intangibles figures came in at $1.2 billion (Q2 2026), $614.0 million (Q1 2026), and $669.5 million (Q4 2025), per Business Quant data.